BRPI0110607B8 - sistema baseado em plasmídeos, método para produzir um vírion de vírus com fita rna negativa, método para produzir um vírion orthomyxoviridae, método para produzir um vírion influenza, método para produzir um vírion influenzapatogênico, método para preparar uma vacina específica de vírus rna de fita negativa e método para gerar um vírus rna de fita negativa atenuado - Google Patents

sistema baseado em plasmídeos, método para produzir um vírion de vírus com fita rna negativa, método para produzir um vírion orthomyxoviridae, método para produzir um vírion influenza, método para produzir um vírion influenzapatogênico, método para preparar uma vacina específica de vírus rna de fita negativa e método para gerar um vírus rna de fita negativa atenuado

Info

Publication number
BRPI0110607B8
BRPI0110607B8 BRPI0110607A BRPI0110607B8 BR PI0110607 B8 BRPI0110607 B8 BR PI0110607B8 BR PI0110607 A BRPI0110607 A BR PI0110607A BR PI0110607 B8 BRPI0110607 B8 BR PI0110607B8
Authority
BR
Brazil
Prior art keywords
producing
virion
rna
negative strand
virus
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Inventor
Hoffmann Erich
Original Assignee
St Jude Childrens Res Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Childrens Res Hospital filed Critical St Jude Childrens Res Hospital
Publication of BR0110607A publication Critical patent/BR0110607A/pt
Publication of BRPI0110607B1 publication Critical patent/BRPI0110607B1/pt
Publication of BRPI0110607B8 publication Critical patent/BRPI0110607B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/00061—Methods of inactivation or attenuation
    • C12N2720/00063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261—Methods of inactivation or attenuation
    • C12N2760/16263—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18661—Methods of inactivation or attenuation
    • C12N2760/18663—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24261—Methods of inactivation or attenuation
    • C12N2770/24263—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/34—Vector systems having a special element relevant for transcription being a transcription initiation element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0110607-4 2000-04-28 2001-04-27 sistema baseado em plasmídeos, método para produzir um vírion de vírus com fita rna negativa, método para produzir um vírion orthomyxoviridae, método para produzir um vírion influenza, método para produzir um vírion influenzapatogênico, método para preparar uma vacina específica de vírus rna de fita negativa e método para gerar um vírus rna de fita negativa atenuado BRPI0110607B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20067900P 2000-04-28 2000-04-28
US60/200,679 2000-04-28
PCT/US2001/013656 WO2001083794A2 (en) 2000-04-28 2001-04-27 Dna transfection system for the generation of infectious influenza virus

Publications (3)

Publication Number Publication Date
BR0110607A BR0110607A (pt) 2004-06-22
BRPI0110607B1 BRPI0110607B1 (pt) 2020-08-11
BRPI0110607B8 true BRPI0110607B8 (pt) 2021-05-25

Family

ID=22742710

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0110607-4 BRPI0110607B8 (pt) 2000-04-28 2001-04-27 sistema baseado em plasmídeos, método para produzir um vírion de vírus com fita rna negativa, método para produzir um vírion orthomyxoviridae, método para produzir um vírion influenza, método para produzir um vírion influenzapatogênico, método para preparar uma vacina específica de vírus rna de fita negativa e método para gerar um vírus rna de fita negativa atenuado

Country Status (25)

Country Link
US (6) US6951754B2 (cg-RX-API-DMAC7.html)
EP (2) EP1317559B1 (cg-RX-API-DMAC7.html)
JP (3) JP2004500842A (cg-RX-API-DMAC7.html)
KR (2) KR100848719B1 (cg-RX-API-DMAC7.html)
CN (2) CN100489107C (cg-RX-API-DMAC7.html)
AT (1) ATE420189T1 (cg-RX-API-DMAC7.html)
AU (3) AU2001259211B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0110607B8 (cg-RX-API-DMAC7.html)
CA (1) CA2406100C (cg-RX-API-DMAC7.html)
CY (1) CY1108735T1 (cg-RX-API-DMAC7.html)
DE (2) DE122011100039I1 (cg-RX-API-DMAC7.html)
DK (1) DK1317559T3 (cg-RX-API-DMAC7.html)
EA (1) EA006311B1 (cg-RX-API-DMAC7.html)
ES (1) ES2319864T3 (cg-RX-API-DMAC7.html)
HU (1) HU229101B1 (cg-RX-API-DMAC7.html)
IL (1) IL152426A (cg-RX-API-DMAC7.html)
MX (1) MXPA02010642A (cg-RX-API-DMAC7.html)
NO (1) NO332080B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ521840A (cg-RX-API-DMAC7.html)
PL (1) PL205955B1 (cg-RX-API-DMAC7.html)
PT (1) PT1317559E (cg-RX-API-DMAC7.html)
SI (1) SI1317559T1 (cg-RX-API-DMAC7.html)
UA (1) UA84254C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001083794A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200208065B (cg-RX-API-DMAC7.html)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
CN100489107C (zh) * 2000-04-28 2009-05-20 圣朱德儿童研究医院 用于产生感染性流感病毒的dna转染系统
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
CN103540568A (zh) * 2002-04-26 2014-01-29 米迪缪尼有限公司 制备流感病毒的多质粒系统
EP1375512B1 (en) * 2002-06-20 2009-07-22 Institut Pasteur Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions
DK1375670T3 (da) * 2002-06-20 2013-09-23 Pasteur Institut Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger
DE10248301A1 (de) * 2002-10-16 2004-04-29 Philipps-Universität Marburg Herstellung eines Lebend-Impfstoffes gegen Influenza-Viren
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
KR101251902B1 (ko) 2003-02-25 2013-04-08 메디뮨 엘엘씨 인플루엔자 백신 조성물의 제조 방법
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
AU2004274860A1 (en) * 2003-05-28 2005-03-31 Wisconsin Alumni Research Foundation Recombinant influenza vectors with a polII promoter and ribozymes
KR100908757B1 (ko) * 2003-05-28 2009-07-22 위스콘신 얼럼나이 리서어치 화운데이션 백신 및 유전자 요법을 위한 고 역가 재조합 인플루엔자바이러스
CA2529647C (en) 2003-06-16 2013-08-13 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
ES2345492T3 (es) * 2003-12-23 2010-09-24 Medimmune, Llc Sistema multiplasmido para la produccion del virus de la gripe.
EP1722815A1 (en) 2004-03-09 2006-11-22 Chiron Corporation Influenza virus vaccines
DE102004013335A1 (de) * 2004-03-17 2005-10-13 TransMIT Gesellschaft für Technologietransfer mbH Impfstoff gegen Influenza basierend auf Geflügelpestviren
EP2811027A1 (en) * 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for RSV and PIV vaccines
HUE025727T2 (en) 2004-05-24 2016-04-28 Medimmune Llc Multi-plasmid system for producing influenza virus
EP2530147B1 (en) * 2004-05-25 2014-09-10 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
CA2583698C (en) 2004-10-06 2014-12-02 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
EA200701097A1 (ru) 2004-11-19 2007-10-26 Висконсин Эламни Рисёч Фаундэйшн Рекомбинантные векторы вируса гриппа с тандемными транскрипционными единицами
US7510719B2 (en) * 2004-12-08 2009-03-31 Medimmune, Llc Methods of producing influenza vaccine compositions
CA2592120A1 (en) 2004-12-23 2006-07-06 Medimmune Vaccines, Inc. Non-tumorigenic mdck cell line for propagating viruses
JP5620048B2 (ja) * 2004-12-24 2014-11-05 アボツト・バイオロジカルズ・ベー・ブイＡｂｂｏｔｔ Ｂｉｏｌｏｇｉｃａｌｓ Ｂ．Ｖ． インフルエンザウイルスの救済（ｒｅｓｃｕｅ）
EP1856271A4 (en) * 2005-03-08 2009-11-18 Medimmune Vaccines Inc INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS
BRPI0610503B1 (pt) * 2005-04-21 2022-05-31 University Of Florida Research Foundation Composições compreendendo vírus influenza, polinucleotídeo isolado, polipeptídeo ou vírus reagrupado, bem como construção de expressão de polinucleotídeo, oligonucleotídeo, micro-organismo transgênico, e métodos para a detecção de um vírus influenza que é capaz de infectar um animal canídeo
US7790434B2 (en) * 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
CA2613283A1 (en) * 2005-06-21 2007-01-04 Medimmune Vaccines, Inc. Methods and compositions for expressing a heterologous protease
ES2402061T3 (es) 2005-10-17 2013-04-26 Medimmune, Llc Método de aumento de la replicación del virus influenza
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP5363107B2 (ja) * 2005-11-04 2013-12-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アジュバントを含むスプリットインフルエンザワクチンにおけるｔｈ１／ｔｈ２バランスの変化
NZ567978A (en) 2005-11-04 2011-09-30 Novartis Vaccines & Diagnostic Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
BRPI0618254A2 (pt) 2005-11-04 2011-08-23 Novartis Vaccines & Diagnostic emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido
EP2368573A3 (en) 2005-11-04 2013-05-01 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
EP3714900A1 (en) 2005-11-04 2020-09-30 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US20110180430A1 (en) 2005-11-04 2011-07-28 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
BR122019013216B8 (pt) * 2006-01-27 2021-07-27 Seqirus Uk Ltd ensaio imunológico para análise de uma vacina contra influenza
WO2007110776A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
AU2012204138B2 (en) * 2006-03-31 2014-02-06 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
JP2009532352A (ja) * 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
AU2014202470B2 (en) * 2006-03-31 2016-08-04 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
KR101436176B1 (ko) 2006-04-19 2014-09-02 메디뮨 엘엘씨 개의 세포 내에서 네거티브-센스 바이러스 ｒｎａ를 발현시키기 위한 방법 및 조성물
US9072701B2 (en) 2006-04-21 2015-07-07 St. Jude Children's Research Hospital Avian influenza viruses, vaccines, compositions, formulations, and methods
US7507411B2 (en) * 2006-06-23 2009-03-24 University Of Saskatchewan Attenuated influenza NS1 variants
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2049662A4 (en) * 2006-07-21 2009-12-30 Medimmune Llc METHODS AND COMPOSITIONS FOR INCREASING REPLICATION CAPACITY OF A FLU VIRUS
KR101586968B1 (ko) * 2006-08-09 2016-01-20 메디뮨 엘엘씨 인플루엔자 헤마글루티닌 및 뉴라미니다제 변이체
EA200970271A1 (ru) 2006-09-11 2010-02-26 Новартис Аг Получение вакцин против вируса гриппа без использования куриных эмбрионов
KR20140075022A (ko) 2006-09-15 2014-06-18 메디뮨 엘엘씨 높은 역가로 바이러스 증식을 지원하는 ｍｄｃｋ 세포주 및 이를 이용한 생물반응기 공정
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
SG177141A1 (en) 2006-12-06 2012-01-30 Novartis Ag Vaccines including antigen from four strains of influenza virus
US20130005028A1 (en) * 2006-12-21 2013-01-03 Smith Larry R Activation of RIG-I Pathway
KR101466326B1 (ko) * 2007-06-15 2014-12-02 주식회사 바이오트라이온 약독화된 인플루엔자 바이러스 및 이를 포함하는 생백신
CA2690196A1 (en) * 2007-06-18 2008-12-24 Medimmune, Llc Influenza b viruses having alterations in the hemaglutinin polypeptide
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
EP2045323A1 (en) * 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
ES2393162T3 (es) 2007-06-27 2012-12-19 Novartis Ag Vacunas antigripales con un contenido reducido de aditivos
CA2934220C (en) 2007-10-02 2019-11-05 Theranos, Inc. Modular point-of-care devices and uses thereof
WO2009068870A1 (en) 2007-11-26 2009-06-04 London School Of Hygiene & Tropical Medicine Method for producing vaccinal viral strain of a virus of the reoviridae family
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
ES2535101T3 (es) 2008-03-18 2015-05-05 Novartis Ag Mejoras en la preparación de antígenos en vacuna de virus de la gripe
EP2574344A1 (en) * 2008-07-11 2013-04-03 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
WO2010036774A1 (en) 2008-09-24 2010-04-01 Medimmune, Llc Methods for purification of viruses
EP2233568A1 (en) 2009-03-19 2010-09-29 Avir Green Hills Biotechnology Research Development Trade AG Novel method for generation of RNA virus
JP2012517416A (ja) 2009-02-10 2012-08-02 ノバルティス アーゲー 増加した量のｈ３抗原を含むインフルエンザワクチン
AU2010212550B2 (en) 2009-02-10 2016-03-10 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
AU2010212547B2 (en) 2009-02-10 2015-03-12 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
JP5818693B2 (ja) * 2009-02-12 2015-11-18 メディミューン，エルエルシー インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
CN102548577A (zh) 2009-04-27 2012-07-04 诺华有限公司 用于抵抗流感的佐剂疫苗
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
US8828406B2 (en) 2009-07-30 2014-09-09 Icahn School Of Medicine At Mount Sinai Influenza viruses and uses thereof
CN104862335A (zh) 2009-07-31 2015-08-26 诺华股份有限公司 反向遗传系统
SG178904A1 (en) 2009-09-10 2012-04-27 Novartis Ag Combination vaccines against respiratory tract diseases
EP2491117B2 (en) * 2009-10-20 2017-06-28 Novartis AG Improved reverse genetics methods for virus rescue
ES2813347T3 (es) 2009-10-26 2021-03-23 Wisconsin Alumni Res Found Virus recombinantes de la influenza de alto título con replicación mejorada en células Vero
CN102051345B (zh) * 2009-11-09 2013-04-17 中国医学科学院医药生物技术研究所 一种抗流行性感冒病毒药物的筛选方法
US9701723B2 (en) * 2010-02-18 2017-07-11 Icahn School Of Medicine At Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
EP3248615A1 (en) 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
US20130183740A1 (en) 2010-06-02 2013-07-18 Avir Green Hills Biotechnology Research Development Trade Ag Novel method for generation of rna virus
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
JP5945282B2 (ja) 2011-01-21 2016-07-05 セラノス， インコーポレイテッド 試料使用の極大化のためのシステム及び方法
CN103403159B (zh) * 2011-02-08 2018-09-14 国立大学法人三重大学 用于基因导入的病毒载体的制造方法
US20130189303A1 (en) 2011-08-02 2013-07-25 Yan Zhou Recombinant swine influenza virus and uses thereof
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
EP2747778B1 (en) 2011-08-26 2017-12-06 Wisconsin Alumni Research Foundation Influenza viruses with mutant pb2 gene segment as live attenuated vaccines
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
CN108164602A (zh) 2011-09-20 2018-06-15 西奈山医学院 流感病毒疫苗及其应用
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
EP2764015A1 (en) 2011-10-07 2014-08-13 Medlmmune, LLC Influenza hemagglutinin variants
CA2852857A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
EP2880154B1 (en) 2012-08-03 2019-05-15 Sanofi Pasteur SA Production of infectious influenza viruses
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
CN108641002A (zh) 2012-12-18 2018-10-12 西奈山伊坎医学院 流感病毒疫苗及其用途
US10401373B1 (en) 2013-02-18 2019-09-03 Theranos Ip Company, Llc Systems and methods for analyte testing and laboratory oversight
US11008628B1 (en) 2013-02-18 2021-05-18 Labrador Diagnostics Llc Systems and methods for analyte testing and laboratory oversight
MX360137B (es) 2013-02-21 2018-10-24 Boehringer Ingelheim Vetmedica Gmbh Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
AU2014290203B2 (en) 2013-07-15 2020-12-24 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
US10422806B1 (en) 2013-07-25 2019-09-24 Theranos Ip Company, Llc Methods for improving assays of biological samples
HUE051628T2 (hu) 2013-12-09 2021-03-01 Sangamo Therapeutics Inc Eljárások és kompozíciók genom-manipulálására
CN103757032B (zh) * 2014-01-28 2017-06-06 中国人民解放军第三0二医院 一种以流感病毒为载体的hcv嵌合疫苗及其制备方法
CA2939942A1 (en) 2014-02-24 2015-08-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration
US11360107B1 (en) 2014-02-25 2022-06-14 Labrador Diagnostics Llc Systems and methods for sample handling
AU2015231353B2 (en) 2014-03-18 2020-11-05 Sangamo Therapeutics, Inc. Methods and compositions for regulation of zinc finger protein expression
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
MA40773A (fr) * 2014-10-02 2017-08-08 Vertex Pharma Variants du virus influenza a
MA40772A (fr) * 2014-10-02 2017-08-08 Vertex Pharma Variants du virus de la grippe a
CN104450695B (zh) * 2014-11-26 2017-08-25 扬州大学 A型流感病毒基因pcr扩增引物及其快速克隆方法
US10889834B2 (en) 2014-12-15 2021-01-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing targeted transgene integration
CA2974699A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
HUE060924T2 (hu) 2015-07-07 2023-04-28 Seqirus Uk Ltd Influenza elleni hatásosság vizsgálata
JP6624736B2 (ja) * 2015-11-18 2019-12-25 国立研究開発法人農業・食品産業技術総合研究機構 インフルエンザウイルス解析装置、インフルエンザウイルス解析方法及びインフルエンザウイルス解析プログラム
US11197925B2 (en) 2016-02-19 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
AU2017272344B2 (en) 2016-06-02 2022-03-03 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
MX2018015755A (es) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
WO2018102586A1 (en) 2016-11-30 2018-06-07 Merial, Inc. Attenuated swine influenza vaccines and methods of making and use thereof
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
US11197926B2 (en) 2017-10-25 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
US12364746B2 (en) 2018-06-21 2025-07-22 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
WO2020033527A2 (en) 2018-08-07 2020-02-13 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
WO2020041311A1 (en) 2018-08-20 2020-02-27 Wisconsin Alumni Research Foundation Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein
WO2020167432A2 (en) 2019-01-23 2020-08-20 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
WO2021150874A1 (en) 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
WO2022051327A1 (en) * 2020-09-02 2022-03-10 St. Jude Children's Research Hospital, Inc. Hemagglutinin modifications for improved influenza vaccine production
WO2022056398A1 (en) * 2020-09-11 2022-03-17 University Of Georgia Research Foundation, Inc. Compositions and methods of use thereof for prevention and treatment of influenza infections
KR102614346B1 (ko) 2020-12-14 2023-12-14 서울대학교산학협력단 Ｈ5ｎ6 재조합 인플루엔자 바이러스, 이의 제조용 조성물, 및 이를 포함하는 백신 조성물
CN121039284A (zh) 2023-03-22 2025-11-28 兰蒂迪克有限公司 表达构建体
WO2025019631A1 (en) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof
WO2025072889A1 (en) * 2023-09-28 2025-04-03 E & E Bioclub Llc Helper-free rescue system for negative-strand rna viruses
WO2025075855A1 (en) * 2023-10-03 2025-04-10 St. Jude Children's Research Hospital, Inc. Reverse genetics vector and associated method of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992522A (en) * 1973-01-24 1976-11-16 The United States Of America As Represented By The Department Of Health, Education And Welfare Temperature-sensitive recombinant mutant viruses and a process for producing same
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5840520A (en) 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5786199A (en) 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
EP0808361A4 (en) 1994-11-16 2001-07-18 St Jude Childrens Res Hospital Novel replication process
DE122008000058I1 (de) 1999-04-06 2009-05-07 Wisconsin Alumni Res Found Rekombinante influenzaviren zur vakzinherstellung und gentherapie
CN100489107C (zh) * 2000-04-28 2009-05-20 圣朱德儿童研究医院 用于产生感染性流感病毒的dna转染系统
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
CN103540568A (zh) 2002-04-26 2014-01-29 米迪缪尼有限公司 制备流感病毒的多质粒系统
ES2345492T3 (es) 2003-12-23 2010-09-24 Medimmune, Llc Sistema multiplasmido para la produccion del virus de la gripe.

Also Published As

Publication number Publication date
US20080311149A1 (en) 2008-12-18
JP5837891B2 (ja) 2015-12-24
CN1856575A (zh) 2006-11-01
JP2013116112A (ja) 2013-06-13
US20080233560A1 (en) 2008-09-25
WO2001083794A2 (en) 2001-11-08
ZA200208065B (en) 2003-11-12
KR100848719B1 (ko) 2008-07-25
EP2085468A1 (en) 2009-08-05
SI1317559T1 (sl) 2009-04-30
US20020164770A1 (en) 2002-11-07
CN101580849A (zh) 2009-11-18
JP5745758B2 (ja) 2015-07-08
UA84254C2 (ru) 2008-10-10
PL205955B1 (pl) 2010-06-30
BR0110607A (pt) 2004-06-22
US7972843B2 (en) 2011-07-05
CY1108735T1 (el) 2014-04-09
AU2006228054B2 (en) 2010-04-29
MXPA02010642A (es) 2004-05-17
DE122011100039I1 (de) 2011-12-08
EA006311B1 (ru) 2005-10-27
PT1317559E (pt) 2009-02-12
CN101580849B (zh) 2012-11-21
AU5921101A (en) 2001-11-12
HU229101B1 (en) 2013-07-29
KR20030072209A (ko) 2003-09-13
US20080311148A1 (en) 2008-12-18
NO332080B1 (no) 2012-06-18
US7312064B2 (en) 2007-12-25
NO20025171D0 (no) 2002-10-28
NZ521840A (en) 2004-11-26
JP2004500842A (ja) 2004-01-15
ATE420189T1 (de) 2009-01-15
CA2406100C (en) 2010-11-02
US20110250232A1 (en) 2011-10-13
US6951754B2 (en) 2005-10-04
BRPI0110607B1 (pt) 2020-08-11
JP2010042030A (ja) 2010-02-25
PL366064A1 (en) 2005-01-24
AU2001259211B2 (en) 2006-07-13
KR100862758B1 (ko) 2008-10-13
CN100489107C (zh) 2009-05-20
US20050186563A1 (en) 2005-08-25
NO20025171L (no) 2002-12-30
CA2406100A1 (en) 2001-11-08
WO2001083794A3 (en) 2003-03-27
EP1317559A2 (en) 2003-06-11
IL152426A (en) 2011-07-31
DK1317559T3 (da) 2009-03-23
DE60137345D1 (de) 2009-02-26
KR20070086094A (ko) 2007-08-27
US8309099B2 (en) 2012-11-13
HUP0303036A2 (hu) 2003-12-29
HK1055992A1 (en) 2004-01-30
IL152426A0 (en) 2003-05-29
EP1317559B1 (en) 2009-01-07
ES2319864T3 (es) 2009-05-14
EA200201164A1 (ru) 2003-10-30
HUP0303036A3 (en) 2004-10-28
AU2006228054A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
BRPI0110607B8 (pt) sistema baseado em plasmídeos, método para produzir um vírion de vírus com fita rna negativa, método para produzir um vírion orthomyxoviridae, método para produzir um vírion influenza, método para produzir um vírion influenzapatogênico, método para preparar uma vacina específica de vírus rna de fita negativa e método para gerar um vírus rna de fita negativa atenuado
US11466257B2 (en) Cell-derived viral vaccines with low levels of residual cell DNA
Vemula et al. Production of adenovirus vectors and their use as a delivery system for influenza vaccines
Mercado-López et al. Highly immunostimulatory RNA derived from a Sendai virus defective viral genome
Elkashif et al. Adenoviral vector‐based platforms for developing effective vaccines to combat respiratory viral infections
Ma et al. Swine influenza vaccines: current status and future perspectives
EP1991571A2 (en) Antiviral agents and vaccines against influenza
EP1270016A4 (en) VACCINE AGAINST AIDS VIRUS CONTAINING A VECTOR OF SENDAI VIRUS
Pandey et al. Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses
Li et al. Generation of a safe and effective live viral vaccine by virus self-attenuation using species-specific artificial microRNA
JP2018525028A5 (cg-RX-API-DMAC7.html)
EP3715459A1 (en) H9 avian influenza vaccine strain which differentiates infected from vaccinated animals, and preparation method therefor
Xiao et al. A replicating modified vaccinia tiantan strain expressing an avian-derived influenza H5N1 hemagglutinin induce broadly neutralizing antibodies and cross-clade protective immunity in mice
US10434166B2 (en) Methods and compositions for in vivo immune stimulation and antigen production
Blanchard et al. Treating influenza and SARS-CoV-2 via mRNA-encoded Cas13a
Dulin et al. Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2
Wittmer-Elzaouk et al. Retroviral self-inactivation in the mouse vagina induced by short DNA
EP2021483B1 (en) Biomolecule surface display and uses thereof
WO2025149907A1 (en) Influenza vaccines
Wu et al. Protective immunity elicited by a pseudotyped baculovirus-mediated bivalent H5N1 influenza vaccine
Das et al. ADVANCING VACCINE DEVELOPMENT AND DELIVERY: THE ROLE OF GENETIC ENGINEERING
Sun et al. Influenza virus activates human immunodeficiency virus type-1 gene expression in human CD4-expressing T cells through an NF-κB-dependent pathway
US20250352628A1 (en) Non-toxic destruction of cancer cells using viral vectored injections
Melnichuk et al. Complexes of oligoribonucleotides with D-mannitol inhibit the interaction of SARS-CoV-2 Spike pseudotyped lentiviral particles with host cells
Maalouf et al. Facile Conjugation Method of CpG‐ODN Adjuvant to Intact Virions for Vaccine Development

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/04/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 27/04/2021